{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:08:00Z","timestamp":1784009280627,"version":"3.55.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004705","name":"King Mongkut's University of Technology Thonburi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biologicals.2022.08.007","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T05:03:39Z","timestamp":1662699819000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD)"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-6272","authenticated-orcid":false,"given":"Aliyu Maje","family":"Bello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowaluck Maprang","family":"Roshorm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2022.08.007_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2017.02249","article-title":"Immunopathogenesis and virus-host interactions of enterovirus 71 in patients with hand, foot and mouth disease","volume":"8","author":"Cox","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/nsr\/nwv038","article-title":"Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth disease","volume":"2","author":"Lei","year":"2015","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.biologicals.2022.08.007_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7774\/cevr.2017.6.1.4","article-title":"Enterovirus 71 infection and vaccine","volume":"6","author":"Yi","year":"2017","journal-title":"Clin Exp Vac Res"},{"key":"10.1016\/j.biologicals.2022.08.007_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00430-016-0465-y","article-title":"Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy","volume":"205","author":"Aswathyraj","year":"2016","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coviro.2014.03.007","article-title":"Update on enterovirus 71 infection","volume":"5","author":"Huang","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(13)70342-6","article-title":"Hand, foot, and mouth disease in China, 2008-12: an epidemiological study","volume":"14","author":"Xing","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biologicals.2022.08.007_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2014.29","article-title":"EV71 vaccines: a milestone in the history of global vaccine development","volume":"3","author":"Lu","year":"2014","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.biologicals.2022.08.007_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib9","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/cid\/ciz1114","article-title":"Effectiveness and safety of an inactivated enterovirus 71 vaccine in children aged 6-71 months in a phase IV study","volume":"71","author":"Guan","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biologicals.2022.08.007_bib10","first-page":"159","article-title":"Annex 3 Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines (inactivated)","volume":"1030","author":"Griffiths","year":"2021","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.biologicals.2022.08.007_bib11","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1016\/j.vaccine.2019.08.031","article-title":"Regulatory aspects of quality and safety for live recombinant viral vaccines against infectious diseases in Japan","volume":"37","author":"Sakurai","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.micinf.2014.11.004","article-title":"Towards broadly protective polyvalent vaccines against hand, foot and mouth disease","volume":"17","author":"Liu","year":"2015","journal-title":"Microb Infect"},{"key":"10.1016\/j.biologicals.2022.08.007_bib13","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2022.08.007_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2022.08.007_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2022.08.007_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2016.73","article-title":"EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases","volume":"5","author":"Mao","year":"2016","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.biologicals.2022.08.007_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/14760584.2016.1138862","article-title":"EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)","volume":"15","author":"Mao","year":"2016","journal-title":"Expet Rev Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib18","first-page":"4917","article-title":"WHO working group meeting to develop WHO Recommendations to assure the quality","volume":"38","author":"Lei","year":"2020","journal-title":"saf eff. enterovirus 71 Vac"},{"key":"10.1016\/j.biologicals.2022.08.007_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0034834","article-title":"Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates","volume":"7","author":"Chou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib20","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.vaccine.2013.03.015","article-title":"A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine","volume":"31","author":"Cheng","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib21","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.vaccine.2019.02.023","article-title":"Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan","volume":"37","author":"Huang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12250-020-00294-3","article-title":"From monovalent to multivalent vaccines, the exploration for potential preventive strategies against hand, foot, and mouth disease (HFMD)","volume":"36","author":"He","year":"2021","journal-title":"Virol Sin"},{"key":"10.1016\/j.biologicals.2022.08.007_bib23","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/14712598.2014.935330","article-title":"Update on the development of enterovirus 71 vaccines","volume":"14","author":"Kung","year":"2014","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.biologicals.2022.08.007_bib24","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1099\/vir.0.80784-0","article-title":"Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys","volume":"86","author":"Arita","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib25","doi-asserted-by":"crossref","first-page":"9386","DOI":"10.1128\/JVI.02856-06","article-title":"An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys","volume":"81","author":"Arita","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib26","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1128\/JVI.00289-14","article-title":"Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice","volume":"88","author":"Meng","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib27","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.2174\/1381612822666160720165613","article-title":"Development of novel miRNA-based vaccines and antivirals against enterovirus 71","volume":"22","author":"Yee","year":"2016","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.biologicals.2022.08.007_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-41285-z","article-title":"Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice","volume":"9","author":"Yee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.biologicals.2022.08.007_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virusres.2006.12.005","article-title":"Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides","volume":"125","author":"Foo","year":"2007","journal-title":"Virus Res"},{"key":"10.1016\/j.biologicals.2022.08.007_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-7-106","article-title":"Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection","volume":"7","author":"Chang","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.biologicals.2022.08.007_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0264-410X(01)00385-1","article-title":"Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus","volume":"20","author":"Wu","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib32","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1016\/j.vaccine.2015.10.103","article-title":"Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection","volume":"33","author":"Kim","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/831282","article-title":"Immunological evaluation and comparison of different EV71 vaccine candidates","author":"Chou","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-11-80","article-title":"Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge","volume":"11","author":"Zhang","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.biologicals.2022.08.007_bib35","first-page":"1","article-title":"Characterization of the enterovirus 71 VP1 protein as a vaccine candidate","volume":"55","author":"Zhou","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2018.09.018","article-title":"Induction of immune responses by a novel recombinant fusion protein of enterovirus A71 in BALB\/c mice","volume":"105","author":"Issaro","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbrc.2012.11.035","article-title":"Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice","volume":"430","author":"Wang","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biologicals.2022.08.007_bib38","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2008.03.041","article-title":"Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection","volume":"26","author":"Chen","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib39","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2005.12.047","article-title":"Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71","volume":"24","author":"Chen","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/14728214.10.1.185","article-title":"Transgenic plants in the biopharmaceutical market","volume":"10","author":"Twyman","year":"2005","journal-title":"Expet Opin Emerg Drugs"},{"key":"10.1016\/j.biologicals.2022.08.007_bib41","volume":"vol. 89","author":"Kirnbauer","year":"1992"},{"key":"10.1016\/j.biologicals.2022.08.007_bib42","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/jvi.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4161\/hv.6.5.11023","article-title":"Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in CervarixTM, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine","volume":"6","author":"Deschuyteneer","year":"2010","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1982.03320390074052","article-title":"The newly licensed hepatitis B vaccine characteristics and indications for use","volume":"247","author":"Krugman","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.biologicals.2022.08.007_bib45","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1001\/jama.1984.03340450028021","article-title":"Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA","volume":"251","author":"Scolnick","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.biologicals.2022.08.007_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(10)61030-6","article-title":"Efficacy and safety of a recombinant hepatitis e vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial","volume":"376","author":"Zhu","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2022.08.007_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0057601","article-title":"Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps","volume":"8","author":"Ku","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib48","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1080\/21645515.2015.1053675","article-title":"Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice","volume":"11","author":"Sun","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.biologicals.2022.08.007_bib49","first-page":"1","article-title":"Characterization of human enterovirus71 virus-like particles used for vaccine antigens","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib50","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-018-3797-7","article-title":"Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71","volume":"163","author":"Wang","year":"2018","journal-title":"Arch Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1023\/A:1024071514438","article-title":"Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells","volume":"25","author":"Hu","year":"2003","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.biologicals.2022.08.007_bib52","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3748\/wjg.v12.i6.921","article-title":"Expression, purification and characterization of enterovirus-71 virus-like particles","volume":"12","author":"Chung","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib53","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.vaccine.2008.01.058","article-title":"Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge","volume":"26","author":"Chung","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib54","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.vaccine.2011.12.081","article-title":"Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles","volume":"30","author":"Lin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib55","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.vaccine.2013.05.019","article-title":"Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-015-1780-x","article-title":"EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge Microbiology","volume":"9","author":"Wang","year":"2016","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.biologicals.2022.08.007_bib57","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.vaccine.2015.03.034","article-title":"High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice","volume":"33","author":"Zhang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1128\/JVI.01848-13","article-title":"Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms","volume":"88","author":"Ye","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2180-13-287","article-title":"Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses","volume":"13","author":"Zhao","year":"2013","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib60","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7150\/thno.7457","article-title":"Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop","volume":"4","author":"Xu","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.biologicals.2022.08.007_bib61","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1080\/21645515.2019.1649554","article-title":"Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris","volume":"16","author":"Yang","year":"2020","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.biologicals.2022.08.007_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/vim.2007.0089","article-title":"Identification of human CD4 + T-cell epitopes on the VP1 capsid protein of enterovirus 71","volume":"21","author":"Foo","year":"2008","journal-title":"Viral Immunol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0165659","article-title":"Immunodominant IgM and IgG Epitopes recognized by antibodies induced in enterovirus A71-Associated hand, foot and mouth disease patients","volume":"11","author":"Aw-Yong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcv.2018.06.001","article-title":"Genome-wide linear B-cell epitopes of enterovirus 71 in a hand, foot and mouth disease (HFMD) population","volume":"105","author":"Zhang","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1743-422X-9-26","article-title":"Enterovirus 71 viral capsid protein linear epitopes: identification and characterization","volume":"9","author":"Gao","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.biologicals.2022.08.007_bib66","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.micinf.2007.06.002","article-title":"Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide","volume":"9","author":"Foo","year":"2007","journal-title":"Microb Infect"},{"key":"10.1016\/j.biologicals.2022.08.007_bib67","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2011.04.010","article-title":"Identification and characterization of a cross-neutralization epitope of Enterovirus 71","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib68","article-title":"Characterization and specificity of the linear epitope of the Enterovirus 71 VP2 protein","volume":"55","author":"T.K","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.biologicals.2022.08.007_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-11-79","article-title":"Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice","volume":"11","author":"Li","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.biologicals.2022.08.007_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2da932d4-8654-45c8-bf83-7b3b09dbc146","article-title":"Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon","volume":"7","author":"Tian","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002895","article-title":"A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved \u201cknob\u201d region of VP3 protein","volume":"8","author":"Kiener","year":"2014","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.biologicals.2022.08.007_bib72","first-page":"1","article-title":"Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity","volume":"7","author":"Jia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.biologicals.2022.08.007_bib73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"Dna vaccines: immunology, application, and optimization","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-0556-5-6","article-title":"DNA vaccine constructs against enterovirus 71 elicit immune response in mice","volume":"5","author":"Tung","year":"2007","journal-title":"Genet Vaccine Ther"},{"key":"10.1016\/j.biologicals.2022.08.007_bib75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4236\/wjv.2014.41006","article-title":"Human enterovirus 71 DNA vaccine constructs containing 5\u2019UTR with complete internal ribosome entry site sequence stimulated improved anti-human enterovirus 71 neutralizing immune responses","volume":"4","author":"Mat-Rahim","year":"2014","journal-title":"World J Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib76","first-page":"35","article-title":"Enhancing immune responses of EV71 VP1 DNA vaccine by co-inoculating plasmid IL- 12 or GM-CSF expressing vector in mice","volume":"62","author":"Peng","year":"2016","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12026-015-8637-1","article-title":"GITRL as a genetic adjuvant enhances enterovirus 71 VP1 DNA vaccine immunogenicity","volume":"62","author":"Yuan","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.biologicals.2022.08.007_bib78","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1016\/j.vaccine.2007.01.120","article-title":"Chemical adjuvants for plasmid DNA vaccines","volume":"25","author":"Greenland","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2022.08.007_bib79","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.micinf.2006.01.021","article-title":"Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71","volume":"8","author":"Chiu","year":"2006","journal-title":"Microb Infect"},{"key":"10.1016\/j.biologicals.2022.08.007_bib80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/IAI.00795-07","article-title":"Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates","volume":"76","author":"Si","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.biologicals.2022.08.007_bib81","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2478\/v10136-012-0032-9","article-title":"Construction and evaluation of a novel Bacillus subtilis spores-based enterovirus 71 vaccine","volume":"11","author":"Cao","year":"2013","journal-title":"J Appl Biomed"},{"key":"10.1016\/j.biologicals.2022.08.007_bib82","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00705-012-1589-z","article-title":"Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71","volume":"158","author":"Yu","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib83","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10529-019-02695-1","article-title":"Recombinant lactococcus lactis secreting viral protein 1 of enterovirus 71 and its immunogenicity in mice","volume":"41","author":"Xu","year":"2019","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.biologicals.2022.08.007_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0021757","article-title":"Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous Human Enterovirus 71 strains in mice","volume":"6","author":"Meng","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.antiviral.2012.05.017","article-title":"Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1","volume":"95","author":"Premanand","year":"2012","journal-title":"Antivir Res"},{"key":"10.1016\/j.biologicals.2022.08.007_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0055536","article-title":"Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice","volume":"8","author":"Premanand","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virusres.2012.06.014","article-title":"Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice","volume":"168","author":"Kolpe","year":"2012","journal-title":"Virus Res"},{"key":"10.1016\/j.biologicals.2022.08.007_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0003692","article-title":"Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease","volume":"9","author":"Tsou","year":"2015","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.biologicals.2022.08.007_bib89","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1128\/CMR.5.3.328","article-title":"Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens","volume":"5","author":"Cardenas","year":"1992","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.biologicals.2022.08.007_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-1656(99)00107-8","article-title":"Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines","volume":"73","author":"Liljeqvist","year":"1999","journal-title":"J Biotechnol"},{"key":"10.1016\/j.biologicals.2022.08.007_bib91","article-title":"Inactivated enterovirus 71 vaccine produced by 200-L scale serum-free microcarrier bioreactor system provides cross-protective efficacy in human SCARB2 transgenic mouse","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib92","first-page":"1","article-title":"A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.biologicals.2022.08.007_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178259","article-title":"An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice","volume":"12","author":"In","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biologicals.2022.08.007_bib94","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1016\/j.vaccine.2016.06.058","article-title":"Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges","volume":"34","author":"Yan","year":"2016","journal-title":"Vaccine"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105622000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105622000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:15:35Z","timestamp":1760922935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105622000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":94,"alternative-id":["S1045105622000562"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2022.08.007","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD)","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2022.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}